Neurogene Statistics
Total Valuation
Neurogene has a market cap or net worth of $304.84 million. The enterprise value is $41.51 million.
Important Dates
The next estimated earnings date is Monday, March 23, 2026, after market close.
| Earnings Date | Mar 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Neurogene has 15.49 million shares outstanding. The number of shares has increased by 60.75% in one year.
| Current Share Class | 15.49M |
| Shares Outstanding | 15.49M |
| Shares Change (YoY) | +60.75% |
| Shares Change (QoQ) | +0.54% |
| Owned by Insiders (%) | 10.06% |
| Owned by Institutions (%) | 56.64% |
| Float | 5.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.12 |
| P/TBV Ratio | 1.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.39, with a Debt / Equity ratio of 0.04.
| Current Ratio | 18.39 |
| Quick Ratio | 18.10 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16,218.50 |
Financial Efficiency
Return on equity (ROE) is -42.25% and return on invested capital (ROIC) is -28.53%.
| Return on Equity (ROE) | -42.25% |
| Return on Assets (ROA) | -26.91% |
| Return on Invested Capital (ROIC) | -28.53% |
| Return on Capital Employed (ROCE) | -35.63% |
| Weighted Average Cost of Capital (WACC) | 14.97% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$795,607 |
| Employee Count | 107 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +18.35% in the last 52 weeks. The beta is 2.04, so Neurogene's price volatility has been higher than the market average.
| Beta (5Y) | 2.04 |
| 52-Week Price Change | +18.35% |
| 50-Day Moving Average | 18.65 |
| 200-Day Moving Average | 20.98 |
| Relative Strength Index (RSI) | 58.92 |
| Average Volume (20 Days) | 105,299 |
Short Selling Information
The latest short interest is 3.59 million, so 23.18% of the outstanding shares have been sold short.
| Short Interest | 3.59M |
| Short Previous Month | 3.54M |
| Short % of Shares Out | 23.18% |
| Short % of Float | 71.12% |
| Short Ratio (days to cover) | 23.37 |
Income Statement
| Revenue | n/a |
| Gross Profit | -69.72M |
| Operating Income | -97.31M |
| Pretax Income | -85.13M |
| Net Income | -85.13M |
| EBITDA | -94.21M |
| EBIT | -97.31M |
| Earnings Per Share (EPS) | -$4.12 |
Full Income StatementBalance Sheet
The company has $265.41 million in cash and $10.21 million in debt, with a net cash position of $255.20 million or $16.48 per share.
| Cash & Cash Equivalents | 265.41M |
| Total Debt | 10.21M |
| Net Cash | 255.20M |
| Net Cash Per Share | $16.48 |
| Equity (Book Value) | 265.54M |
| Book Value Per Share | 17.97 |
| Working Capital | 255.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$77.24 million and capital expenditures -$1.17 million, giving a free cash flow of -$78.41 million.
| Operating Cash Flow | -77.24M |
| Capital Expenditures | -1.17M |
| Free Cash Flow | -78.41M |
| FCF Per Share | -$5.06 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Neurogene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -60.75% |
| Shareholder Yield | -60.75% |
| Earnings Yield | -28.69% |
| FCF Yield | -26.43% |
Analyst Forecast
The average price target for Neurogene is $40.14, which is 103.96% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $40.14 |
| Price Target Difference | 103.96% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 178.68% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Neurogene has an Altman Z-Score of 7.06 and a Piotroski F-Score of 2.
| Altman Z-Score | 7.06 |
| Piotroski F-Score | 2 |
